Clinical Trials

    Showing 1 - 4 of 4 Muscular Dystrophy

    Global Study of Del-desiran for the Treatment of DM1 (HARBOR)

    Status: Enrolling

    Investigator: Ericka Greene

    Study Coordinator: Aramide Balogun

    Phone: 713.441.6955

    The study consists of a Screening Period of up to 6 weeks and 54-week Treatment Period. The anticipated duration is approximately 60 weeks. Participants will be randomized to receive an intravenous infusion of either del-desiran or placebo at the ... Read more >

    Myotonic Dystrophy Compilation of Clinical Findings

    Status: Enrolling

    Investigator: Ericka Greene

    Study Coordinator: Anjana Singh

    Phone: 713.441.9120

    The purpose of this protocol is to make available clinical findings, including blood pressure, pulmonary function tests, cardiac function tests, clinical evaluations, cognitive evaluations, performance tests, medications, routine blood work evaluatio... Read more >

    Protective Genetic Factors Against Neurological Diseases

    Status: Open Not Enrolling

    Investigator: Jun Li

    Study Coordinator: Aramide Balogun

    Phone: 713.441.6955

    This study aims to look at the genetic differences between individuals with neurological disorders and healthy controls, and whether these genetic differences contribute to nerve conduction speeds. We expect that this study will identify a small clus... Read more >

    RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

    Status: Enrolling

    Investigator: Bing Liao

    Study Coordinator: KaDeesia Brown

    Phone: 713.441.9120

    Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), an... Read more >